Relief Therapeutics Holding SA

About Relief Therapeutics Holding SA

Relief Therapeutics is a Swiss, commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for specialty, rare, and ultra-rare diseases. Their mission is to provide therapies that significantly improve the condition and quality of life for rare disease patients, enabling them to live their best possible lives and achieve their full potential.

Products & Services

RLF-TD011:A therapy under development for Epidermolysis Bullosa, with recent FDA responses, Rare Pediatric Disease Designation, and positive clinical trial results.

PKU GOLIKE:A treatment for Phenylketonuria (PKU), with clinical trial results and related publications announced.

RLF-OD032:A therapy in a proof-of-concept study, with topline results expected.

Specialties

Rare Diseases Ultra-Rare Diseases Specialty Therapies Patent-Protected Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing T: - FT: Royalty Financing	A: 11000000 MR: - FA: up to $11 million FAN: 11000000	D: 2024-08-05 FD: 2024-08-05	1 investors
2	RT: Share Subscription Facility T: - FT: Share Subscription Facility	A: 50000000 MR: - FA: CHF 50 million FAN: 50000000	D: 2024-02-28 FD: 2024-02-28	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: CHF 5 million FAN: 5000000	D: 2023-06-23 FD: 2023-06-23	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: CHF 5 million FAN: 5000000	D: 2023-06-16 FD: 2023-06-16	1 investors

Royalty Financing Latest

2024-08-05

$11.0M

1 investor (Pro only)

Share Subscription Facility 2024-02-28

$50.0M

Private Placement 2023-06-23

$5.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paolo Galfetti

Chief Business Officer

G

Giorgio Reiner

Chief Scientific Officer

J

Jeremy Meinen

CHIEF FINANCIAL OFFICER AND TREASURER

R

Raghuram Selvaraju

Chairman of the Board

P

Peter de Svastich

Member of the Board of Directors

G

Gregory Van Beek

Member of the Board of Directors

View 4 more team members with Pro

Unlock Full Team Directory

Recent News